Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig + Casdatifan in 1L Advanced ccRCC
NCT07000149Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised trial of volrustomig and casdatifan in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Number of participants with adverse events (AEs) and serious adverse events (SAEs). Started Jul 2025; status: active, not recruiting.
02
Drugs
volrustomigcasdatifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07000149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000149.